Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Flexion Therapeutics (FLXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,020,044
  • Shares Outstanding, K 37,640
  • Annual Sales, $ 360 K
  • Annual Income, $ -137,480 K
  • 36-Month Beta 0.84
  • Price/Sales 2,983.40
  • Price/Cash Flow N/A
  • Price/Book 4.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.50 +6.04%
on 05/25/18
29.10 -7.08%
on 06/20/18
-0.49 (-1.78%)
since 05/22/18
3-Month
21.11 +28.09%
on 03/28/18
29.10 -7.08%
on 06/20/18
+3.54 (+15.06%)
since 03/22/18
52-Week
19.06 +41.87%
on 10/26/17
32.25 -16.16%
on 10/06/17
+6.88 (+34.13%)
since 06/22/17

Most Recent Stories

More News
Flexion Therapeutics Named one of Boston Business Journal's Best Places to Work for the Second Year in a Row

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named as one of the Boston Business Journal's "Best Places to Work" for the second year in a row. Flexion was ranked among the...

FLXN : 27.04 (-0.22%)
Free Stock Performance Review on Zoetis and Three Additional Generic Drugs Stocks

Stock Research Monitor: FLXN, MNTA, and PETQ

PETQ : 24.01 (+0.21%)
MNTA : 21.20 (-1.17%)
FLXN : 27.04 (-0.22%)
Anokion Elects Michael Clayman, M.D., as Chairman of its Board of Directors

Anokion ("Anokion" or the "Company"), a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced that Michael D....

FLXN : 27.04 (-0.22%)
Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)

Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, today announced the expanded deployment of its Extended Workbench...

FLXN : 27.04 (-0.22%)
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to eight new employees for an aggregate of 50,000 shares of common stock. The Compensation Committee of the...

FLXN : 27.04 (-0.22%)
Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights

-- Positive developments in Medicare reimbursement with CMS issuing Q code for ZILRETTA (effective 7/1/18) and recommending dedicated J code (effective 1/1/19)

FLXN : 27.04 (-0.22%)
Flexion Therapeutics Names David Arkowitz as Chief Financial Officer

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that David Arkowitz has been named Chief Financial Officer (CFO). Mr. Arkowitz brings more than 25 years of finance and operations leadership experience...

FLXN : 27.04 (-0.22%)
Flexion Therapeutics Announces ZILRETTA(R) (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the Centers for Medicare and Medicaid Services (CMS) has included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) on its...

FLXN : 27.04 (-0.22%)
Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, May 8, 2018. Flexion's management...

FLXN : 27.04 (-0.22%)
Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress

Results from preclinical osteoarthritis (OA) models demonstrate relief of pain, functional

FLXN : 27.04 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade FLXN with:

Business Summary

Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United...

See More

Key Turning Points

2nd Resistance Point 28.41
1st Resistance Point 27.76
Last Price 27.01
1st Support Level 26.76
2nd Support Level 26.41

See More

52-Week High 32.25
Fibonacci 61.8% 27.21
Last Price 27.01
Fibonacci 50% 25.65
Fibonacci 38.2% 24.10
52-Week Low 19.06

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar